Skip to Main Content
School of Public Health

​
  • Admissions
  • Research
  • Education
  • Practice
​
Search
  • Newsroom
    • School News
    • SPH This Week Newsletter
    • SPH in the Media
    • SPH This Year Magazine
    • News Categories
    • Contact Us
  • Research
    • Centers and Groups
  • Academic Departments
    • Biostatistics
    • Community Health Sciences
    • Environmental Health
    • Epidemiology
    • Global Health
    • Health Law, Policy & Management
  • Education
    • Degrees & Programs
    • Public Health Writing
    • Workforce Development Training Centers
    • Partnerships
    • Apply Now
  • Admissions
    • Applying to BUSPH
    • Request Information
    • Degrees and Programs
    • Why Study at BUSPH?
    • Tuition and Funding
    • SPH by the Numbers
    • Events and Campus Visits
    • Admissions Team
    • Student Ambassadors
    • Frequently Asked Questions
  • Events
    • Public Health Conversations
    • Full Events Calendar
    • Alumni and Friends Events
    • Commencement Ceremony
    • SPH Awards
  • Practice
    • Activist Lab
  • Careers & Practicum
    • For Students
    • For Employers
    • For Faculty & Staff
    • For Alumni
    • Graduate Employment & Practicum Data
  • Public Health Post
    • Public Health Post Fellowship
  • About
    • SPH at a Glance
    • Advisory Committees
    • Strategy Map
    • Senior Leadership
    • Accreditation
    • Diversity, Equity, Inclusion, and Justice
    • Directory
    • Contact SPH
  • Support SPH
    • Big Ideas: Strategic Directions
    • Faculty Research and Development
    • Future of Public Health Fund
    • Generation Health
    • idea hub
    • Public Health Conversations
    • Public Health Post
    • Student Scholarship
    • How to Give
    • Contact Development and Alumni Relations
  • Students
  • Faculty & Staff
  • Alumni
  • Directory
Read More News
health inequities

US Excess Deaths Continued to Rise Even After the COVID-19 Pandemic

Erin Johnston
Global Health

Student Receives 2025 Pulitzer Center Reporting Fellowship

Tuberculosis Vaccine Passes Milestone.

May 23, 2017
Twitter Facebook

vaccine-injectionA team of investigators that includes a School of Public Health researcher has announced that two new studies of DAR-901, an investigational vaccine against tuberculosis (TB), have moved it to the forefront of new vaccines in development for global control of the deadly infectious disease.

The research team, led by Dartmouth’s Geisel School of Medicine, said the results of the studies represent “major milestones” on the path to approval of the vaccine. C. Robert Horsburgh, professor of epidemiology, is a collaborator on the studies.

Tuberculosis is the leading infectious disease cause of death in the world, and there is a global effort to eradicate it by 2035. According to modeling by the World Health Organization, a new vaccine will be required to meet that ambitious elimination goal. The Dartmouth candidate, DAR-901, is an inactivated vaccine made from a non-pathogenic bacterium that is genetically related to Mycobacterium tuberculosis, the cause of human tuberculosis. An earlier form of the vaccine was used in the DarDar Trial, a seven-year study in Tanzania sponsored by the US National Institutes of Health involving patients with HIV infection who at birth had received BCG, the current tuberculosis vaccine. In that trial, the inactivated vaccine was effective as a booster in preventing tuberculosis.

The two new studies on DAR-901, conducted in collaboration with Aeras, were published in the journal PLOS ONE. In the pre-clinical study, BCG was administered first followed by a booster immunization with either DAR-901 or a second dose of BCG. Protection against subsequent tuberculosis challenge was greater with the DAR-901 booster than with the BCG booster.

In the clinical study, DAR-901 was administered to adults living in the United States who had received BCG at birth. A three-dose series of the vaccine was safe and well-tolerated. In addition, DAR-901 induced immune responses that were similar to those seen with the vaccine shown effective in the DarDar trial.

“Taken together, these two studies suggest that the new scalable vaccine formulation is likely to prove as effective as the original formulation—which would make it the first protective TB vaccine in humans since BCG, which was introduced almost a century ago,” said Ajit Lalvani, director of the Tuberculosis Research Centre, National Heart and Lung Institute, Imperial College London, and a member of the DAR-901 development team.

A larger randomized trial is underway in Tanzania to determine if DAR-901 prevents the earliest stage of infection with tuberculosis, before symptoms are apparent. In February, the 650 adolescents in this “prevention of infection” study completed receiving three doses of DAR-901 or placebo. The vaccine was again observed to be safe and well-tolerated. The trial is sponsored by Global Health Innovative Technology Fund (Japan), and results of vaccine efficacy will be available in late 2018.

Explore Related Topics:

  • tuberculosis
  • vaccine
  • Share this story

Share

Tuberculosis Vaccine Passes Milestone

  • Facebook
  • Reddit
  • LinkedIn
  • Email
  • Print
  • More
  • Twitter

More about SPH

Sign up for our newsletter

Get the latest from Boston University School of Public Health

Subscribe

Also See

  • About
  • Newsroom
  • Contact
  • Support SPH

Resources

  • Students
  • Faculty & Staff
  • Alumni
  • Directory
  • Boston University School of Public Health
  • 715 Albany Street, Boston, MA 02118
  • © 2021 Trustees of Boston University
  • DMCA
  • Facebook
  • YouTube
  • LinkedIn
  • Instagram
  • TikTok
© Boston University. All rights reserved. www.bu.edu
Boston University Masterplate
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.